Related Experiment Video
Updated: May 12, 2026
Large-Scale Preparation of Synovial Fluid Mesenchymal Stem Cell-Derived Exosomes by 3D Bioreactor Culture
Published on: July 26, 2022
Targeting osteoarthritis with small extracellular vesicle therapy: potential and perspectives
Alba González-Rodríguez1, F Javier De Toro2,3,4, Alberto Jorge-Mora5
1Servicio de Cirugía Plástica, Complexo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain.
Abstract:
Osteoarthritis (OA) is a degenerative joint disease marked by inflammation, cartilage degradation, and pain, leading to a significant decline in quality of life. Recent advancements in extracellular vesicle (EV) research have introduced new therapeutic possibilities, with small extracellular vesicles (sEV) emerging as a promising strategy for OA treatment. sEV, particularly those derived from mesenchymal stem cells (MSCs), synoviocytes, chondrocytes, and induced pluripotent stem cells (iPSCs), demonstrate substantial anti-inflammatory and regenerative properties. These nanosized vesicles facilitate intercellular communication, delivering bioactive molecules that can modulate the joint microenvironment, promote chondrogenesis, and alleviate pain. Preclinical and early clinical studies indicate that sEV-based therapies may slow disease progression and enhance cartilage repair in OA patients. Despite the promising potential, challenges remain, including standardizing isolation techniques, understanding underlying mechanisms, and navigating regulatory pathways. This systematic review analyzes relevant publications published between 2019 and 2025, highlighting the therapeutic and biomarker potential of sEV in OA. Although there is substantial ongoing research into sEV and biomarkers, the fundamental understanding of OA pathogenesis remains largely unchanged, with most studies continuing to focus on established mechanisms of cartilage degradation, inflammation, and subchondral bone changes. The findings suggest that while therapeutic research into sEV is progressing, advancements in unraveling new pathophysiological mechanisms of OA are more limited. Further research is essential to optimize therapeutic protocols and establish clinical efficacy, marking sEV-based therapies as a promising but evolving approach for OA treatment.
Insights
Small extracellular vesicles (sEVs) show therapeutic potential for osteoarthritis (OA) by reducing inflammation and promoting cartilage repair. While research is advancing, further studies are needed to optimize sEV treatments for OA.
Area of Science:
- Biomedical Engineering
- Regenerative Medicine
- Orthopedics
Background:
- Osteoarthritis (OA) is a degenerative joint disease characterized by inflammation, cartilage loss, and pain, significantly impacting patient quality of life.
- Extracellular vesicles (EVs), particularly small extracellular vesicles (sEVs), are emerging as a promising therapeutic avenue for OA.
- sEVs, derived from various cell types like mesenchymal stem cells (MSCs), possess anti-inflammatory and regenerative properties beneficial for OA treatment.
Purpose of the Study:
- To systematically review the therapeutic and biomarker potential of sEVs in osteoarthritis (OA) based on literature published between 2019 and 2025.
- To analyze the progress and limitations in sEV-based OA research and understand OA pathogenesis.
Main Methods:
- Systematic literature review of publications from 2019 to 2025 focusing on sEVs and OA.
- Analysis of studies investigating sEV therapeutic applications, mechanisms of action, and biomarker potential in OA.
- Evaluation of research progress in understanding OA pathophysiology in relation to sEV research.
Main Results:
- sEVs demonstrate significant anti-inflammatory and regenerative capabilities, modulating the joint microenvironment to promote chondrogenesis and reduce pain.
- Preclinical and early clinical data suggest sEV therapies can potentially slow OA progression and enhance cartilage repair.
- Despite therapeutic advancements, the fundamental understanding of OA pathogenesis has seen limited change, with research focusing on established mechanisms.
Conclusions:
- sEV-based therapies represent a promising, albeit evolving, approach for OA treatment, with potential to slow disease progression and improve cartilage repair.
- Standardization of sEV isolation, elucidation of mechanisms, and regulatory navigation are key challenges that need addressing.
- Further research is crucial to optimize therapeutic protocols and confirm the clinical efficacy of sEVs for osteoarthritis management.
More Related Videos
Related Concept Videos
01:19Mesenchymal Stem Cells
01:29Microorganisms in Medicine and Therapeutics